A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition.

[1]  J. Fruchart,et al.  Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[2]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[3]  J. Fruchart,et al.  Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. , 1990, Clinical chemistry.

[4]  J. Bard,et al.  Profiles of apolipoproteins and apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias. , 1988, Clinical chemistry.

[5]  R. Desnick,et al.  Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. , 1987, The Journal of clinical investigation.

[6]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[7]  J. Fruchart,et al.  Apolipoprotein A-I containing lipoproteins in coronary artery disease. , 1987, Atherosclerosis.

[8]  J. Fruchart,et al.  Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. , 1987, Biochemical and biophysical research communications.

[9]  J. Fruchart,et al.  Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. , 1987, Clinical chemistry.

[10]  S. Grundy,et al.  Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. , 1985, Journal of lipid research.

[11]  K. Woodcroft,et al.  Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs. , 1985, Journal of lipid research.

[12]  E. Stange,et al.  Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. , 1985, Atherosclerosis.

[13]  G. Vanhoutte,et al.  [Assay of serum apolipoprotein A-II by electro-immunodiffusion on ready-for-use plates. Clinical applications]. , 1984, Annales de biologie clinique.

[14]  A. Zinsmeister,et al.  Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. , 1983, The New England journal of medicine.

[15]  D. Sommariva,et al.  Effects of procetofen on seum serum lipids and lipoproteins and on plasma post-heparin lipase activities in type II and in type IV hyperlipoproteinemic patients , 1983 .

[16]  J. Fruchart,et al.  Lipoproteins, apolipoproteins and coronary artery disease assessed by coronary arteriography , 1982 .

[17]  P. Alaupovic.  The role of apolipoproteins in lipid transport processes , 1982, La Ricerca in clinica e in laboratorio.

[18]  D. Sommariva,et al.  Inactivation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cultured human blood mononuclear cells by procetofenic acid. , 1982, Pharmacological research communications.

[19]  C. Kallenberg.  CYCLOPHOSPHAMIDE AND SUPPRESSOR CELL FUNCTION , 1981, The Lancet.

[20]  C. Wilhelmsson,et al.  Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors--determination of apolipoprotein D. , 1980, Atherosclerosis.

[21]  W. Riesen,et al.  Apoproteins and lipids as discriminators of severity of coronary heart disease. , 1980, Atherosclerosis.

[22]  R Monaghan,et al.  Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Wilhelmsson,et al.  Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors. Apolipoprotein A-I levels in male survivors of myocardial infarction. , 1980, Atherosclerosis.

[24]  B. Lewis,et al.  Quantitative studies of ver low densit lipoprotein: conversion to low densit lipoprotein in normal controls and primar hperlipidaemic states and the role of direct secretion of low densit lipoprotein in heterozgous familial hpercholesterolaemia , 1980, European journal of clinical investigation.

[25]  G. Assmann,et al.  Lipoprotein and apoprotein values in coronary angiography patients. , 1980, Artery.

[26]  A. Soutar,et al.  Simultaneous measurement of apolipoprotein B turnover in very-low-and low-density lipoproteins in familial hypercholesterolaemia. , 1977, Atherosclerosis.

[27]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[28]  A. Børresen,et al.  SERUM-HIGH-DENSITY-LIPOPROTEIN AND ATHEROSCLEROTIC HEART-DISEASE , 1976, The Lancet.

[29]  P. Alaupovic,et al.  Studies on the interaction of concanavalin A with major density classes of human plasma lipoproteins. Evidence for the specific binding of lipoprotein B in its associated and free forms , 1974, FEBS letters.

[30]  P. Alaupovic,et al.  Studies on the composition and structure of plasma lipoproteins. Distribution of lipoprotein families in major density classes of normal human plasma lipoproteins. , 1972, Biochimica et biophysica acta.